See What HealthDay Can Do For You
Contact Us

MRSA Isolate Acquired vanA Resistance During Therapy

Patient had a serious skin condition that may have predisposed to bacterial colonization

THURSDAY, April 17, 2014 (HealthDay News) -- Researchers report that a bloodstream infection of methicillin-resistant Staphylococcus aureus (MRSA) in a patient with a serious skin condition acquired vancomycin resistance during antibiotic therapy, according to a report published in the April 17 issue of the New England Journal of Medicine.

Flávia Rossi, M.D., Ph.D., from the Universidade de São Paulo in Brazil, and colleagues report of a patient with a bloodstream infection caused by a strain of MRSA that was susceptible to vancomycin (designated BR-VSSA) but during antibiotic therapy acquired the vanA gene cluster and became resistant to vancomycin (designated BR-VRSA).

The researchers found that both strains belong to the sequence type 8 community-associated genetic lineage, which carries the staphylococcal chromosomal cassette mec type IVa and the S. aureus protein A gene type t292. Both are related to MRSA lineage USA300 phylogenetically. A conjugative plasmid (55,706 bp [pBRZ01]) was identified that carried the vanA cluster and readily transferred to other staphylococci. There are DNA sequences harbored in the pBRZ01 plasmid that are typical of the plasmid-associated replication genes rep24 or rep21 witnessed in community-associated MRSA strains from Australia (pWBG745).

"The presence and dissemination of community-associated MRSA containing vanA could become a serious public health concern," the authors write.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.